Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients

Table 4 Comparison of molecular characteristics of colorectal cancers with and without CDX2 expression n (%)

Parameters	CDX2-retained671 (94.1)	Loss of CDX2 expression42 (5.9)	P value
CIMP			< 0.001
CIMP-0	271 (40.4)	5 (11.9)
CIMP-low	374 (55.7)	17 (40.5)
CIMP-high	26 (3.9)	20 (47.6)
MSI			< 0.001
MSS	587 (87.5)	28 (66.7)
MSI-low	35 (5.2)	2 (4.7)
MSI-high	49 (7.3)	12 (28.6)
KRAS (n = 674)			0.577
Wild type	466 (73.5)	31 (77.5)
Mutant type	168 (26.5)	9 (22.2)
BRAF (n = 707)			0.0051
Wild type	634 (95.2)	34 (82.9)
Mutant type	32 (4.8)	7 (17.1)
CK7 expression			< 0.0011
No-expression	624 (93.0)	24 (57.1)
Increased	47 (7.0)	18 (42.9)
CK20 expression			< 0.001
Retained	593 (88.4)	27 (64.3)
Decreased	78 (11.6)	15 (35.7)

¹Fisher’s exact test. Cut-off for increased CK7 expression: ≥ 10% of tumor cells showing membranous stain, cut-off for decreased CK20 expression: < 50% of tumor cells showing membranous stain. CIMP: CpG island methylator phenotype; MSI: Microsatellite instability; MSS: Microsatellite stable; CK: Cytokeratin.